成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開
諾華制藥CEO:中國(guó)蘊(yùn)藏大商機(jī)

諾華制藥CEO:中國(guó)蘊(yùn)藏大商機(jī)

吉奧夫?科爾文 2013-04-03
諾華掌門人喬?吉莫內(nèi)斯稱,中國(guó)市場(chǎng)已經(jīng)成為諾華全球最大的十個(gè)市場(chǎng)之一。諾華不僅在中國(guó)擁有龐大的業(yè)務(wù)規(guī)模,而且還在迅速增長(zhǎng)。去年,它的中國(guó)市場(chǎng)增長(zhǎng)了24%。而且,中國(guó)政府前不久表示,還將提高城鄉(xiāng)地區(qū)的醫(yī)療支出,預(yù)計(jì)中國(guó)市場(chǎng)還將持續(xù)增長(zhǎng)。

????是的,我們采取了一種不同的方法。大約10年前開始,我們就啟動(dòng)了一種所謂的“途徑”法。我們知道,通常對(duì)于一種罕見的疾病來說,如果有了一個(gè)癥狀非常相似的患者群,我們就能了解這種特定疾病的分子途徑。

????但是這個(gè)患者群可能很小。

????雖然很小,但是一個(gè)非常同質(zhì)的患者群可以讓我們研究這種疾病以及導(dǎo)致該疾病的分子途徑。然后我們會(huì)研發(fā)能阻斷這種途徑的藥物,再有條理地?cái)U(kuò)展到受相同分子途徑影響的其它疾病領(lǐng)域。所以所謂“重磅藥品”的定義將會(huì)有所變化,一個(gè)藥品不再只對(duì)應(yīng)一個(gè)疾病領(lǐng)域,而是可能能夠用于治療三種、四種甚至五種疾病。

????舉個(gè)例子?

????比如我們的癌癥藥物依維莫斯(Afinitor)。它是一種雷帕霉素靶蛋白(mTOR,人類細(xì)胞中的一種蛋白質(zhì))抑制劑,mTOR的分子途徑與多種疾病有關(guān)。我們一開始研發(fā)依維莫斯是為了治療腎細(xì)胞癌,然后我們開始在許多其它癌癥上測(cè)試依維莫斯的效果。我們最近剛剛證實(shí),乳腺癌 也與mTOR的分子途徑有關(guān),而這將對(duì)每年22萬(wàn)名晚期乳腺癌患者提供幫助。這就是一個(gè)例子,最初用于治療腎細(xì)胞癌的藥物,最終也能治療乳腺癌。綜合效應(yīng)使它成為了一個(gè)重磅藥物。

????研發(fā)是諾華的一項(xiàng)巨大投資,你們的競(jìng)爭(zhēng)對(duì)手也是一樣。你們?nèi)绾螐耐顿Y的每一美元中獲得更好的研發(fā)效果?

????問得好。人人都想提高研發(fā)效果,我們發(fā)現(xiàn)了幾點(diǎn):首先必須找到對(duì)的科學(xué)家。所以我們給科學(xué)家們建立了研究中心。我們沒有要求他們集中在一個(gè)特定的地點(diǎn),我們?cè)诿绹?guó)、西歐都建立了研究中心,而且我們正在上海建立另一個(gè)研究中心。人才在哪里,我們就去哪里。這是第一點(diǎn)。

????第二點(diǎn)是要保持在研發(fā)上的強(qiáng)大投入。在諾華公司,我們承諾把大約20%的銷售額投入到研發(fā)上。對(duì)于我們的藥品業(yè)務(wù)規(guī)模來說,就是每年投入90多億美元。所以我們有了對(duì)的人才,和對(duì)的投資數(shù)額,我們認(rèn)為這是讓我們成功的第一部分。

????然后你還要有正確的研究方法,從不同的角度來思考,到底應(yīng)該如何進(jìn)行藥物開發(fā),我認(rèn)為那就是途徑法。

????對(duì)你來說,在美國(guó)和西歐以外,增長(zhǎng)潛力最大的地區(qū)是哪里?

????我們在中國(guó)的業(yè)務(wù)規(guī)模非常龐大,而且增長(zhǎng)很快。中國(guó)市場(chǎng)剛剛成為我們的全球十大市場(chǎng)之一。去年我們的中國(guó)市場(chǎng)增長(zhǎng)了24%。而且中國(guó)政府前不久表示,將提高城鄉(xiāng)地區(qū)的醫(yī)療支出,所以我們認(rèn)為中國(guó)將是一個(gè)持續(xù)增長(zhǎng)的地區(qū)。另一個(gè)地區(qū)是俄羅斯。俄羅斯有一個(gè)問題,就是它的人口數(shù)量在下降。俄羅斯政府表示將提高醫(yī)療水平,扭轉(zhuǎn)人口規(guī)模下降趨勢(shì)。另外還有很多發(fā)展中國(guó)家,我們認(rèn)為都是增長(zhǎng)中的市場(chǎng),也都進(jìn)行了大量投資。

????你們?cè)谀切┦袌?chǎng)中的業(yè)務(wù)模式是否很不一樣?因?yàn)槟莾旱拇蠖鄶?shù)民眾都得自己掏錢治病。

????Yes, we took a different approach. Starting about 10 years ago, we started what's called the pathways approach, where we understand the molecular pathway of a particular disease, usually in a rare disease where you have a very homogeneous patient population.

????But maybe a very small population.

????A small population, but a very homogeneous patient population that allows us to study the disease and the molecular pathway that leads to that disease. We then develop a drug that can interrupt that pathway, and then we look to mechanistically expand into other disease areas that are impacted by the same pathway. So essentially it doesn't mean that blockbusters will go away, but the definition of a blockbuster will change pretty dramatically away from having one disease area to a drug that maybe is active in three or four or even five diseases.

????What's an example?

????An example is our oncology drug called Afinitor, which is an mTOR [a type of protein in human cells] inhibitor. The mTOR pathway is implicated in many different types of diseases. So we initially developed Afinitor in renal cell cancer, and then we started testing Afinitor in many other cancers. Breast cancer is another indication that we just received approval for, and that's now going to help more than 220,000 patients every year who have advanced breast cancer. So here's an example of a drug that started in renal cell cancer, has expanded into breast cancer, and then there are a number of other indications. That together will make it a blockbuster.

????R&D is a huge investment for Novartis, as it is for your competitors. How do you get more than the other guys from a dollar of R&D?

????A good question -- everybody's trying to increase productivity in research and development. We've found a couple of things. First you have to find the right scientists. So we have built research centers where the scientists are. We have not asked them to come to a particular location. We've built research centers in the U.S., in Europe, and we're building one in Shanghai. So we're going where the talent is. That's No. 1.

????The second is keeping spending strong in research and development. At Novartis we've made the commitment to spend about 20% of sales on research and development. In our pharma business, that's over $9 billion a year that we invest. So if you have the right talent and the right amount of spending, we find that that's the first part of success.

????Then you have to have the right approach, and I think that's the pathways approach, taking a different look at how we're going to discover and develop drugs.

????Where are the geographic areas of growth for you outside the U.S. and Western Europe?

????We have a very large and growing business in China, which has just become one of our top 10 markets. Last year it grew 24%. The Chinese government has made a massive commitment to improving health care among rural and urban Chinese, and so we see that as a continued growth area. Another area is Russia. Russia has a problem. It has a declining population. And the government in Russia has made the commitment to improve access to health care in ways that will reverse that population decline. There are many developing countries in which we're investing quite heavily as growth areas.

????In markets like that, isn't it a very different business? Those people are paying for their own medical care for the most part.

掃描二維碼下載財(cái)富APP
女人一区二区三区电影| 中文字幕欧美精品一区二区| 国产v片在线播放免费无遮挡| 亚洲国产精品自产拍在线播放| 国产熟女一区二区三区五月婷小说| 国产精品美女被遭强扒开双腿| 野花香日本大全免费观看| 一本加勒比少妇人妻无码精品| 久久亚洲精精品中文字幕| 久久精品国产一区二区三区| 日韩不卡毛片Av免费高清| 久久久久精品国产AV免费| 国产强伦姧在线观看无码| 亚洲精品无码专区国产乱码| 国产亚洲综合在线观看播放页| 亚洲AV永久无码精品无码流畅亚洲| 亚洲成AV人无码综合在线观看| 亚洲国产精品一区二区三区| 曰韩少妇内射免费播放| 久久久久久黃色網站免費 | 国产成av人片在线观看天堂无码| 欧美性理论片在线观看片免费| 看免费视频一区二区三区| 亚洲区欧美中文字幕久久| 精品人妻aⅴ区乱码久久蜜臀| 久久久久久精品免费免费英国| 亚洲成Av人片在线观看无码影片| 叫床很激烈的年轻水嫩大学生| 欧美精品一区二区精品久久| 人妻AV综合天堂一区| 亚洲人成欧美中文字幕| 麻豆人人妻人人妻人人片av| 天天爱天天做天天添天天欢| 夜夜夜夜曰天天天天| WWW插插插无码视频网站| 亚洲成AV成人片在线观看天堂| 亚洲成AV人无码不卡影片| 国产无码免费视频在线| 欧美成aⅴ人高清免费| 性高朝久久久久久久久久| 欧美一级片在线免费看|